03/29/16 - 12:36 PM EDT
A panel of outside experts selected by the FDA are reviewing a Parkinson's disease drug developed by Acadia Pharmaceuticals.
03/28/16 - 06:00 AM EDT
The outcome of the panel vote is hugely important to Acadia. An affirmative decision would most likely compel FDA to approve Nuplazid by its decision date of May 1.
03/27/16 - 08:30 AM EDT
A small plurality of health care investors believe biotech stocks will outperform the broader market for the balance of 2016, according to a survey conducted in March by JPMorgan.
03/25/16 - 10:30 AM EDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
03/24/16 - 09:58 AM EDT
TheStreet's senior columnist Adam Feuerstein answers reader questions about biotech stocks.
03/21/16 - 01:07 PM EDT
36 doctors, all experts in Duchenne muscular dystrophy, have written a letter to the U.S. Food and Drug Administration urging the agency to approve Sarepta Therapeutics' experimental therapy eteplirsen.
03/21/16 - 11:15 AM EDT
Based on these study results, BioMarin intends to file pegvaliase for approval with the FDA by the end of the year, 'subject to further discussions' with the agency.
03/19/16 - 11:20 AM EDT
TheStreet's biotech columnist Adam Feuerstein answers reader questions about biotech stocks.
03/17/16 - 08:01 AM EDT
Gilead's cancer business, a hoped-for source of future earnings growth, has hit some turbulence.
03/16/16 - 12:33 PM EDT
A jury ruled in favor of Amgen in a patent infringement case covering a new class of cholesterol-lowering drugs that the biotech company filed against Regeneron Pharmaceuticals and Sanofi.